CD274 and triple-negative breast carcinoma: However, a bispecific antibody targeting TGF-β/PD-L1, developed by Youzhi You Bio, has shown enhanced antitumor activity in triple-negative breast cancer models, suggesting that combined targeting of TGF-β and PD-L1 could be an effective therapeutic strategy [41].